CLINICAL AND MORPHOLOGICAL FEATURES OF HEREDITARY OVARIAN CANCER

Germ-line mutations in BRCA1 and BRCA2 genes are the most established risk factors for hereditary breast and ovarian cancers. The purpose of the study was to analyze BRCA1/2 testing in ovarian cancer patients. Materials and methods. We analyzed 222 patients with ovarian cancer (OC) who underwent genetic testing. Results. Recurrent Slavic mutations in these genes were detected in 60/222 (27%) patients.104 patients lacked any clinical signs of hereditary form of the disease, however BRCA1/2 genetic defects were identified among 11 (11%) of these women. BRCA1/2-associated carcinomas were characterized by more advanced stage at diagnosis and predominance of high-grade serous histological tumor subtype. Conclusion. These results emphasize the need for BRCA1/2 testing for all patients with OC. BRCA1/2-associated carcinomas have clinical and pathological cgaracteristics, which should be considered while planning therapy.

1. Fact Sheets by Cancer [Internet] URL: http://globocan.iarc.fr/Pages/ fact_sheets_cancer.aspx (cited: 28.01.2017).

2. Axel E.M. Incidence and Mortality from Malignant Tumors of the Female Reproductive System in Russia. Oncogynecology. 2015; (1): 6–15 [in Russian]

3. Kaprin A.D., Starinskiy V.V., Petrova G.V. The state of oncologi-cal care for the population of Russia in 2014. Moscow, 2015; 236. [in Russian]

4. Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignant neoplasms in Russia in 2014 (morbidity and mortality). Moscow, 2016; 250. [in Russian]

5. Worldwide data. World Cancer Research Fund International [Inter-net]. URL: http://www.wcrf.org/int/cancer-facts-figures/worldwide-data (дата обращения: 28.01.2017).

6. Staples J., Goodm A. PARP Inhibitors in Ovarian Cancer. InTech, 2012. doi: 10.5772/52888.

7. Konstantinopoulos P.A., Ceccaldi R., Shapiro G.I., D’Andrea A.D. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov. 2015 Nov; 5 (11): 1137–54. doi: 10.1158/2159-8290.CD-15-0714.

8. European Society for Medical Oncology. BRCA in breast cancer: ESMO Clinical Recommendations, 2015.

9. Moyer V.A. U.S. Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014 Feb 18; 160 (4): 271–81.

10. National Comprehensive Cancer Network (NCCN). Guidelines for detection, prevention, & risk reduction: genetic/familial high-risk assessment: breast and ovarian. 2015.

11. Kast K., Rhiem K., Wappenschmidt B., Hahnen E., Hauke J., Bluemcke B., Zarghooni V., Herold N., Ditsch N., Kiechle M., Braun M., Fischer C., Dikow N., Schott S., Rahner N., Niederacher D., Fehm T., Gehrig A., Mueller-Reible C., Arnold N., Maass N., Borck G., de Gregorio N., Scholz C., Auber B., Varon-Manteeva R., Speiser D., Horvath J., Lichey N., Wimberger P., Stark S., Faust U., Weber B.H., Emons G., Zachariae S., Meindl A., Schmutzler R.K., Engel C.; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. J Med Genet. 2016 Jul; 53 (7): 465–71. doi: 10.1136/jmedgenet-2015-103672.

12. Teixeira N., Mourits M.J., Vos J.R., Kolk D.M., Jansen L., Oosterwijk J.C., Bock G.H. Ovarian cancer in BRCA1/2 mutation carriers: The impact of mutation position and family history on the cancer risk. Maturitas. 2015 Oct; 82 (2): 197–202. doi: 10.1016/j.maturitas.2015.07.001.

13. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Rich-ardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M., Jackson S.P., Smith G.C., Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 7035 (434): 917–21. doi: 10.1038/nature03445.

14. Tassone P., Tagliaferri P., Perricelli A., Blotta S., Quaresima B., Martelli M.L., Goel A., Barbieri V., Costanzo F., Boland C.R., Venuta S. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 2003 Apr 22; 88 (8): 1285–91.

15. Suspitsin E.N., Sherina N.Y., Ponomariova D.N., Sokolenko A.P., Iyevleva A.G., Gorodnova T.V., Zaitseva O.A., Yatsuk O.S., Togo A.V., Tkachenko N.N., Shiyanov G.A., Lobeiko O.S., Krylova N.Y., Matsko D.E., Maximov S.Y., Urmancheyeva A.F., Porhanova N.V., Imyanitov E.N. High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients. Hered. Cancer Clin. Pract. 2009; 7 (1): 5. doi: 10.1186/1897-4287-7-5.

16. Tan D.S., Kaye S.B. Chemotherapy for Patients with BRCA1 and BRCA2–Mutated Ovarian Cancer: Same or Different? American Society of Clinical Oncology Educational Book. 2015; 35: 114–21. doi: 10.14694/ EdBook_AM.2015.35.114.

17. Mavaddat N., Barrowdale D., Andrulis I.L., Domchek S.M., Eccles D., Nevanlinna H., Ramus S.J., Spurdle A., Robson M., Sherman M., Mulligan A.M., Couch F.J., Engel C., McGuffog L., Healey S., Sinilnikova O.M., Southey M.C., Terry M.B., Goldgar D., O’Malley F., John E.M., Janavicius R., Tihomirova L., Hansen T.V., Nielsen F.C., Osorio A., Stavropoulou A., Benítez J., Manoukian S., Peissel B., Barile M., Volorio S., Pasini B., Dolcetti R., Putignano A.L., Ottini L., Radice P., Hamann U., Rashid M.U., Hogervorst F.B., Kriege M., van der Luijt R.B.; HEBON, Peock S., Frost D., Evans D.G., Brewer C., Walker L., Rogers M.T., Side L.E., Houghton C.; EMBRACE, Weaver J., Godwin A.K., Schmutzler R.K., Wappenschmidt B., Meindl A., Kast K., Arnold N., Niederacher D., Sutter C., Deissler H., Gadzicki D., Preisler-Adams S., Varon-Mateeva R., Schönbuchner I., Gevensleben H., Stoppa-Lyonnet D., Belotti M., Barjhoux L.; GEMO Study Collaborators, Isaacs C., Pesh-kin B.N., Caldes T., de la Hoya M., Cañadas C., Heikkinen T., Heikkilä P., Aittomäki K., Blanco I., Lazaro C., Brunet J., Agnarsson B.A., Arason A., Barkardottir R.B., Dumont M., Simard J., Montagna M., Agata S., D’Andrea E., Yan M., Fox S.; kConFab Investigators, Rebbeck T.R., Rubinstein W., Tung N., Garber J.E., Wang X., Fredericksen Z., Pan-kratz V.S., Lindor N.M., Szabo C., Offit K., Sakr R., Gaudet M.M., Singer C.F., Tea M.K., Rappaport C., Mai P.L., Greene M.H., Sokolenko A., Imyanitov E., Toland A.E., Senter L., Sweet K., Thomassen M., Gerdes A.M., Kruse T., Caligo M., Aretini P., Rantala J., von Wachenfeld A., Henriksson K.; SWE-BRCA Collaborators, Steele L., Neuhausen S.L., Nussbaum R., Beat-tie M., Odunsi K., Sucheston L., Gayther S.A., Nathanson K., Gross J., Walsh C., Karlan B., Chenevix-Trench G., Easton D.F., Antoniou A.C.; Consortium of Investigators of Modifiers of BRCA1/2. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012 Jan; 21 (1): 134–47. doi: 10.1158/1055-9965.EPI-11-0775.

18. Bolton K.L., Chenevix-Trench G., Goh C., Sadetzki S., Ramus S.J., Karlan B.Y., Lambrechts D., Despierre E., Barrowdale D., McGuffog L., Healey S., Easton D.F., Sinilnikova O., Benítez J., García M.J., Neuhausen S., Gail M.H., Hartge P, Peock S., Frost D., Evans D.G., Eeles R., Godwin A.K., Daly M.B., Kwong A., Ma E.S., Lázaro C., Blanco I., Montagna M., D’Andrea E., Nicoletto M.O., Johnatty S.E., Kjær S.K., Jensen A., Høgdall E., Goode E.L., Fridley B.L., Loud J.T., Greene M.H., Mai P.L., Chetrit A., Lubin F., Hirsh-Yechezkel G., Glendon G., Andrulis I.L., Toland A.E., Senter L., Gore M.E., Gourley C., Michie C.O., Song H., Tyrer J., Whit-temore A.S., McGuire V., Sieh W., Kristoffersson U., Olsson H., Borg Å., Levine D.A., Steele L., Beattie M.S., Chan S., Nussbaum R.L., Moysich K.B., Gross J., Cass I., Walsh C., Li A.J., Leuchter R., Gordon O., Garcia-Closas M., Gayther S.A., Chanock S.J., Antoniou A.C., Pharoah P.D.; EMBRACE; kConFab Investigators; Cancer Genome Atlas Research Network. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012; 4 (307): 382–90. doi: 10.1001/jama.2012.20.

19. Sun C., Li N., Ding D., Weng D., Meng L., Chen G., Ma D. The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis. PloS one. 2014; 5 (9). doi: 10.1371/journal.pone.0095285.